Translation of MRS for determining human pathology into the clinic: acceptance testing for breast, prostate and barrett'

Funded Activity Summary

Magnetic resonance spectroscopy (MRS), for many organs, provides the pathological diagnosis with an accuracy approaching 100%. In the case of breast lesions, it discriminates accurately between benign and malignant and, for overt carcinomas, predicts the status of the regional lymph nodes without the need to biopsy the node. For some lesions, such as Barrett’s oesophagus, distinction between dysplasia’s of no immediate concern to the patient and those apparently committed to early progression to clinical cancer, can be made by the MRS method. A statistical classification method, (SCS) has been developed whereby there are now mathematical classifiers available for the testing acceptance of the method in the clinical setting. Acceptance testing of MRS technology, with the mathematical classifiers integrated in the automated software, for the pathology and prognosis from a biopsy specimen in: ·           Breast clinic (Dr Malycha, Royal Adelaide) for both pathology and nodal involvement from fine needle aspiration biopsy ·           Gastrointestinal clinic (Dr Falk. Strathfield Private) for Barrett’s oesophagus ·           Urology clinic (Dr Katelaris, Sydney Adventist Hospital) for prostate.

Funded Activity Details

Start Date: 01-01-2003

End Date: 01-01-2004

Funding Scheme: NHMRC Development Grants

Funding Amount: $160,000.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Diagnostic Applications

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cancer | informatics | magnetic resonance spectroscopy | pathology | prognosis

Related Links